A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Eli Lilly and Company
Eli Lilly and Company
Astellas Pharma Inc
AstraZeneca
Incyte Corporation
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
M.D. Anderson Cancer Center
Novartis
Northwestern University
Eikon Therapeutics
AstraZeneca
BeiGene
BioAtla, Inc.
M.D. Anderson Cancer Center
Checkpoint Therapeutics, Inc.
Phanes Therapeutics
Genentech, Inc.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
SCRI Development Innovations, LLC
Nektar Therapeutics
Eli Lilly and Company
Northwestern University
NextCure, Inc.
AbbVie
Mereo BioPharma
Eli Lilly and Company
Northwestern University
AbbVie
Clovis Oncology, Inc.
M.D. Anderson Cancer Center
AstraZeneca
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
UNC Lineberger Comprehensive Cancer Center
CanBas Co. Ltd.
Stanford University
Georgetown University
Centro Nacional de Investigaciones Oncologicas CARLOS III
Millennium Pharmaceuticals, Inc.
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company